antithymocyte globulin

Phase 3Small molecule

Sanofi

antithymocyte globulin is one of 237 small molecule programs targeting Aplastic Anemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

236

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aplastic AnemiaActive, not recruiting

LymphomaActive, not recruiting

Kidney TransplantActive, not recruiting

Dyskeratosis CongenitaActive, not recruiting

AnemiaActive, not recruiting

Bone Marrow TransplantationActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Severe Aplastic AnemiaActive, not recruiting

Type 1 DiabetesActive, not recruiting

Hematologic MalignanciesActive, not recruiting

Aplastic AnemiaPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Kidney TransplantPhase 3

Active, not recruiting

Dyskeratosis CongenitaPhase 2/Phase 3

Active, not recruiting

AnemiaPhase 2

Active, not recruiting

Bone Marrow TransplantationPhase 2

Active, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

Severe Aplastic AnemiaPhase 2

Active, not recruiting

Type 1 DiabetesPhase 2

Active, not recruiting

Hematologic MalignanciesPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

antithymocyte globulin

Sanofi

Phase 3

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Hematologic Malignancies

NCT04098393

Q4 2026

Phase 2Active, not recruiting

Antibody-Mediated Rejection

NCT05156710

Q2 2030

Phase 2Not yet recruiting

Diabetes

NCT07216391

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome3 trials

Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome

Completed·PPETHEMA Foundation·Phase 4·NCT00488436·25 enrolled

A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00001839·182 enrolled

Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome

Unknown status·OOffice of Rare Diseases (ORD)·Phase 2·NCT00466843·54 enrolled

Hematologic Malignancies3 trials

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT01621477·34 enrolled

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

Completed·FFate Therapeutics·Phase 1·NCT00890500·12 enrolled

A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Conditioning Prior to Ex-vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04098393·39 enrolled

Hematopoietic Stem Cell Transplantation2 trials

Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation

Completed·—·Phase 3·NCT05166967·204 enrolled

Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation

Unknown status·—·Phase 2·NCT04778618·63 enrolled

Kidney Transplant2 trials

Thymoglobulin Induction in Kidney Transplant Recipients

Unknown status·UUniversity of Oxford·Phase 3·NCT01239563·40 enrolled

Efficacy of Islet After Kidney Transplantation

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00468117·24 enrolled

Type 1 Diabetes2 trials

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00434850·14 enrolled

Islet Transplantation in Type 1 Diabetes

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00434811·48 enrolled

22 more indications

Transplantation2 trials

Completed·MMassachusetts General Hospital·Phase 2·NCT00133367·32 enrolled

Cord Blood Transplantation for Patients With Cancer

Terminated·UUniversity of Chicago·Phase 2·NCT01359254·1 enrolled

Severe Aplastic Anemia2 trials

Comparing Therapies for the Treatment of Severe Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00001626·33 enrolled

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

Completed·MM.D. Anderson Cancer Center·N/A·NCT00427336·9 enrolled

Aplastic Anemia2 trials

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03531736·17 enrolled

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

Completed·MMedical College of Wisconsin·Phase 2·NCT02918292·32 enrolled

Dyskeratosis Congenita1 trial

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00455312·36 enrolled

Stem Cell Transplant1 trial

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Completed·—·Phase 1·NCT00697684·29 enrolled

Treatment1 trial

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00515099·58 enrolled

Myelodysplasia1 trial

Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia

Completed·—·Phase 2·NCT00005937·42 enrolled

Stem Cell Transplantation1 trial

Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00385788·52 enrolled

Hematologic Malignancy1 trial

Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Completed·NNanfang Hospital, Southern Medical University·N/A·NCT02487069·876 enrolled

CML1 trial

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00499889·42 enrolled

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT05156710·48 enrolled

Diabetes1 trial

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

Not yet recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT07216391·60 enrolled

Lymphoma1 trial

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Terminated·SStanford University·Phase 2·NCT00481832·50 enrolled

T1D1 trial

STOP-T1D Low-Dose (ATG)

Terminated·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT04291703·2 enrolled

Refractory1 trial

Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy

Withdrawn· Amgen logo

Amgen·Phase 2·NCT05323617

Anemia1 trial

Medical Treatment for Diamond Blackfan Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00001749·25 enrolled

Bone Marrow Transplantation1 trial

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02702960

Sources

References

[1]
ClinicalTrials.gov — 37 trial records for antithymocyte globulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — antithymocyte globulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for antithymocyte globulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

antithymocyte globulin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2030

Trials by Indication[1]

Myelodysplastic Syndrome3 trials

Hematologic Malignancies3 trials

Hematopoietic Stem Cell Transplantation2 trials

Kidney Transplant2 trials

Type 1 Diabetes2 trials

Transplantation2 trials

Severe Aplastic Anemia2 trials

Aplastic Anemia2 trials

Dyskeratosis Congenita1 trial

Stem Cell Transplant1 trial

Treatment1 trial

Myelodysplasia1 trial

Stem Cell Transplantation1 trial

Hematologic Malignancy1 trial

CML1 trial

Acute Lymphoblastic Leukemia1 trial

Survival1 trial

Sts1 trial

Islet Transplantation1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Antibody-mediated Rejection1 trial

Diabetes1 trial

Lymphoma1 trial

T1D1 trial

Refractory1 trial

Anemia1 trial

Bone Marrow Transplantation1 trial

References

Drug Info

Quick Facts

Related News